Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Prioritizes Cancer And Rare Diseases In Pipeline Shake-Up

Executive Summary

Hours after getting the nod from the FDA for Cablivi, the French drugmaker has had an R&D pipeline overhaul and says it could potentially submit nine new medicines and 25 additional indications to regulatory authorities from 2019 to 2022.

Advertisement

Related Content

Sanofi/Regeneron Cut Praluent List Price As PBMs Look To Maintain Rebate Status Quo
New US Cholesterol Guidelines Hit PCSK9s Hard On Pricing, Value
Dupixent Approved For Severe Asthma With Broader Label Than Other Biologics
Cablivi CHMP Backing Helps Validate Sanofi's €3.9bn Ablynx Purchase

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124633

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel